Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents

• Hoofdauteurs: Ahmed F. Khalil (Auteur), Tarek F. El-Moselhy (Auteur), Eman A. El-Bastawissy (Auteur), Rasha Abdelhady (Auteur), Nancy S. Younis (Auteur), Mervat H. El-Hamamsy (Auteur)
• Formaat: Boek
• Gepubliceerd in: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Mutant isocitrate dehydrogenase (IDH) 2 "IDH2m" acquires a neo-enzymatic activity reducing α-ketoglutarate to an oncometabolite, D-2-hydroxyglutarate (2-HG). Three s-triazine series were designed and synthesised using enasidenib as a lead compound. In vitro anticancer screening via Nationa...